Epigenetic silencing of RASSF1A, PRSS3, or any of the SFRP genes is significantly associated with advanced tumor stage (P < 0.001, P < 0.04, and P < 0.005, respectively) [58]. The gene discussed is PRSS3; the disease is neoplasm.